CymaBay Therapeutics, Inc.
(NASDAQ : CBAY)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.18%178.151.3%$463.55m
CELGCelgene Corporation
0.87%97.351.3%$421.76m
GILDGilead Sciences, Inc.
1.30%67.220.9%$393.54m
BIIBBiogen Inc.
2.14%232.531.3%$354.95m
ILMNIllumina, Inc.
0.88%347.023.5%$270.30m
REGNRegeneron Pharmaceuticals, Inc.
1.69%310.412.6%$232.86m
AAgilent Technologies, Inc.
0.00%69.971.6%$212.08m
VRTXVertex Pharmaceuticals Incorporated
1.57%172.891.9%$197.23m
ARRYArray BioPharma Inc.
55.07%45.898.2%$183.84m
EXASExact Sciences Corporation
0.39%110.2125.3%$183.59m
ALXNAlexion Pharmaceuticals, Inc.
2.40%120.762.0%$176.29m
BMRNBioMarin Pharmaceutical Inc.
4.16%84.214.3%$136.26m
MRTXMirati Therapeutics Inc.
6.23%100.132.5%$113.68m
IONSIonis Pharmaceuticals, Inc.
3.51%64.278.2%$96.36m
INCYIncyte Corporation
4.75%81.402.5%$91.45m

Company Profile

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.